A new molecular therapy against ocular herpes
一种针对眼部疱疹的新分子疗法
基本信息
- 批准号:10363614
- 负责人:
- 金额:$ 46.22万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-08-01 至 2024-01-31
- 项目状态:已结题
- 来源:
- 关键词:AcyclovirAdverse effectsAffinityBindingBiochemicalBiological AvailabilityBlindnessCell CycleCellsClinicalComplexContact LensesCorneaCyclodextrinsDNADNA biosynthesisDNA deliveryDataDevelopmentDistressDoseDrug CombinationsDrug KineticsDrug resistanceEncephalitisEngineeringEye InfectionsFRAP1 geneFlow CytometryFormulationFoscarnetFundingGanciclovirGlycoproteinsGoalsGraft RejectionHerpesvirus 1Herpetic KeratitisInfectionInflammationIntravenousKeratitisKeratoplastyMass Spectrum AnalysisMeasurementModelingModernizationMolecularMorbidity - disease rateMusPathway interactionsPatientsPermeabilityPharmaceutical PreparationsPhosphorylationPost-Translational Protein ProcessingPrevention therapyProphylactic treatmentProtein BiosynthesisProtein Synthesis InhibitorsProteinsProteomeProteomicsPublishingPyrrolidinesRefractory DiseaseReportingResistanceReverse Transcriptase Polymerase Chain ReactionRoleSimplexvirusSolubilitySymptomsTestingTherapeuticThiophenesThymidine KinaseTimeTissuesTopical applicationToxic effectToxicologyTranslationsTreatment EfficacyViralViral ProteinsVirusVirus SheddingWestern Blottinganti-viral efficacyaptameraqueousbaseclinical carecorneal scardesigndisease prognosisdosageimprovedin vivoin vivo evaluationinhibitormouse modelnovelnucleoside analogocular painpharmacokinetics and pharmacodynamicspreventprophylacticreceptorrecurrent infectionsmall moleculesoundtranslational impactviral DNA
项目摘要
Herpes simplex virus type-1 (HSV-1) with limited treatment options is a leading cause of infectious blindness
and an important indication for corneal transplants in the US. The current treatment options include acyclovir
and its derivatives, ganciclovir and foscarnet. All these drugs primarily act upon viral thymidine kinase to inhibit
viral DNA replication and in essence have a similar mechanism of action. While these options are effective and
show promise in reducing ocular HSV-1 infection including herpes stromal keratitis (HSK), emergence of drug
resistance in the recent years has caused significant distress in the clinical care of ocular HSV-1 patients. As a
result, there exists an unmet need for the development of new treatments against HSV-1 especially the ones
that rely on novel modes of action. In our previous 3-year funding period we have characterized two candidates
that target two different stages of HSV-1 infection; viral entry and viral protein synthesis. Against viral entry a
highly effective anti-HSV-1 aptamer (DApt) was developed that targets HSV-1 glycoprotein D (gD). Similarly,
we demonstrated for the first time that a small molecule PDK-1 inhibitor, BX795, blocks HSV-1 protein
synthesis. Both candidates were tested in vivo for topical treatment of corneal HSV-1 infection and we reported
significant improvements in disease prognosis. The major goals for the next funding period are to: (1) improve
the in vivo efficacy of DApt, (2) understand the molecular basis of antiviral action by BX795, and (3) develop
BX795 for systemic treatment of ocular herpes. In the first specific aim, we propose several ways to improve
efficacy. We will engineer therapeutic contact lenses for sustained delivery of DApt, improve DApt formulation
to include permeating agents such as cylodextrins to increase the depth to which the aptamer is delivered into
the corneal tissue, and develop higher efficacy (synergistic or additive) drug combinations using DApt and
BX795 or a nucleoside analog. In the second specific aim, we will decode the molecular mechanisms
responsible for the antiviral activity of BX795 using both biased and unbiased approaches. Focus on the cap-
dependent translation pathways responsible for viral protein synthesis will constitute the biased approach; cell-
free and whole cell proteomic analyses using quantitative mass spectrometry and study of post translational
modifications will constitute unbiased approaches. In the third specific aim, we will comprehensively study the
pharmacokinetic and toxicological profiles of intravenously administered BX795. Using this data, we will finally
understand the safe and effective dosage of BX795 required for the effective inhibition of primary and
reactivated HSV-1 infection of the cornea using murine models of corneal infection. Taken together our studies
will establish novel antiviral mechanisms and help design new prophylactic and therapeutic ways to control
HSV-1 infection of the eye.
治疗选择有限的 1 型单纯疱疹病毒 (HSV-1) 是导致感染性失明的主要原因
也是美国角膜移植的重要适应症。目前的治疗方案包括阿昔洛韦
及其衍生物更昔洛韦和膦甲酸。所有这些药物主要作用于病毒胸苷激酶以抑制
病毒的复制在本质上与DNA有相似的作用机制。虽然这些选择是有效的并且
显示出减少眼部 HSV-1 感染(包括疱疹性基质角膜炎 (HSK))的希望,药物的出现
近年来,耐药性给眼部 HSV-1 患者的临床护理带来了重大困扰。作为一个
因此,开发针对 HSV-1 的新疗法的需求尚未得到满足,尤其是
依赖于新颖的行动模式。在我们之前的 3 年资助期内,我们已经确定了两名候选人
针对 HSV-1 感染的两个不同阶段;病毒进入和病毒蛋白合成。防止病毒进入
开发了针对 HSV-1 糖蛋白 D (gD) 的高效抗 HSV-1 适体 (DApt)。相似地,
我们首次证明小分子 PDK-1 抑制剂 BX795 可以阻断 HSV-1 蛋白
合成。两种候选药物都经过了角膜 HSV-1 感染局部治疗的体内测试,我们报告了
疾病预后显着改善。下一个资助期的主要目标是:(1)改进
DApt 的体内功效,(2) 了解 BX795 抗病毒作用的分子基础,以及 (3) 开发
BX795 用于眼部疱疹的全身治疗。在第一个具体目标中,我们提出了几种改进方法
功效。我们将设计治疗性隐形眼镜以持续输送 DApt,改进 DApt 配方
包括渗透剂,例如环糊精,以增加适体递送到的深度
角膜组织,并使用 DApt 和开发更高功效(协同或相加)的药物组合
BX795 或核苷类似物。在第二个具体目标中,我们将解码分子机制
使用有偏见和无偏见的方法负责 BX795 的抗病毒活性。重点关注帽子——
负责病毒蛋白合成的依赖翻译途径将构成有偏差的方法;细胞-
使用定量质谱法进行游离和全细胞蛋白质组分析以及翻译后研究
修改将构成公正的方法。在第三个具体目标中,我们将全面研究
静脉注射 BX795 的药代动力学和毒理学特征。使用这些数据,我们最终将
了解有效抑制原发性和
使用小鼠角膜感染模型重新激活角膜的 HSV-1 感染。综合我们的研究
将建立新的抗病毒机制并帮助设计新的预防和治疗方法来控制
眼睛 HSV-1 感染。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DEEPAK SHUKLA其他文献
DEEPAK SHUKLA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DEEPAK SHUKLA', 18)}}的其他基金
A small molecule inhibitor of HSV genital infections
HSV 生殖器感染的小分子抑制剂
- 批准号:
10205994 - 财政年份:2018
- 资助金额:
$ 46.22万 - 项目类别:
A small molecule inhibitor of HSV genital infections
HSV 生殖器感染的小分子抑制剂
- 批准号:
9763444 - 财政年份:2018
- 资助金额:
$ 46.22万 - 项目类别:
A new molecular therapy against ocular herpes
一种针对眼部疱疹的新分子疗法
- 批准号:
10557908 - 财政年份:2015
- 资助金额:
$ 46.22万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 46.22万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 46.22万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 46.22万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 46.22万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 46.22万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 46.22万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 46.22万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 46.22万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 46.22万 - 项目类别:
Downsides of downhill: The adverse effects of head vibration associated with downhill mountain biking on visuomotor and cognitive function
速降的缺点:与速降山地自行车相关的头部振动对视觉运动和认知功能的不利影响
- 批准号:
2706416 - 财政年份:2022
- 资助金额:
$ 46.22万 - 项目类别:
Studentship